The Clinical Research Of Intraoperative Topical Use Of5-Fluorouracil Sustained Release Agent In The Treatment Of Advanced Epithelial Ovarian Cancer

Objective：To the prospective study, evaluate on intraoperative topical use of5fluorouracil sustained release agent in the treatment of advanced epithelial ovariancancer therapeutic effect, safety and feasibility.Methods：In2008July～2009December in maternal and child health hospital inJiangxi was satisfied with the ovarian cancer cytoreductive operation, postoperativecombined with chemical treatment, and by postoperative pathology confirmed in90patients with advanced epithelial ovarian cancer patients: prospective study.90patients were randomly divided into three groups,30cases in each group: treatmentgroup (group A) of immediate intraoperative intraperitoneal placement of5fluorour-acil sustained release agent;1in the control group (group B) intraperitoneal cisplatinchemotherapy;2in the control group (group C) intravenous chemotherapy afteroperation of3groups,1-3week TP scheme venous chemotherapy every3weeks,1, atotal of6-8times.All patients were followed-up regularly, the starting time of eachobservation for patients after first days, the deadline for the201203months31daysinto the group of patients, observation of curative effect in the near future, adversereactions and side effects.Results：among the3groups in age, clinical stage, pathological type, histologicalgrade, complicated with ascites and associated with lymph node metastasis, showedno significant difference (P>0.05).3groups of the leucopenia, gastrointestinalreaction, impaired liver function, renal function damage, heat, hair loss and otheraspects of comparison, there were no significant differences between them (P>0.05).3groups in the postoperative complications (incision infection and dehiscence,bdominal abscess, peritonitis and intestinal obstruction due to adhesions) and otheraspects of comparison, there were no significant differences between them (P>0.05).3groups of patients with preoperative, postoperative first times, second times,third times and4times before chemotherapy on serum CA125level is compared, thedifference was not statistically significant (P>0.05).3combinations, with lymph nodemetastasis and ascites, clinical stage III, pathological types, pathological grade of serous III level of patients with preoperative, postoperative first times, second times,third times and4times before chemotherapy on serum CA125level is compared, thedifference was not statistically significant (P>0.05).3groups of patients after12months of local recurrence had a significant difference (P<0.05), after24months,27months of local recurrence is not statistically significant differences (P>0.05),3groups of overall survival and progression-free survival (12months after theoperation,24month,27months) to compare difference not to have statisticalsignificance (P>0.05).Conclusion：Intraoperative topical use of5-fluorouracil sustained release agentintraperitoneal chemotherapy has better curative effect in the near future for theadvanced epithelia ovarian cancer after optimally cytoreductive surgery, and is notincreased in patients with toxic side reaction,the long-term effects need furtherobservation.